Adaptimmune Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $3,222 | $40,901 | $128,231 | $5,678 |
Gross Profit | 3,222 | 40,901 | 125,629 | 2,849 |
EBITDA | -67,974 | -12,859 | 71,014 | -46,431 |
EBIT | -70,809 | -15,677 | 68,269 | -49,259 |
Net Income | -74,215 | -17,617 | 69,521 | -48,503 |
Net Change In Cash | 3,222 | 40,901 | 128,231 | 5,678 |
Free Cash Flow | -35,377 | -54,886 | 46,631 | -32,289 |
Cash | 91,139 | 116,741 | 211,810 | 140,670 |
Basic Shares | 1,513,810 | 1,534,613 | 1,559,183 | 1,451,241 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $178,032 | $60,281 | $27,148 | $6,149 |
Gross Profit | 177,962 | 50,423 | -100,578 | -104,941 |
EBITDA | -52,665 | -128,198 | -155,593 | -155,679 |
EBIT | -63,890 | -138,038 | -161,664 | -162,245 |
Net Income | -70,814 | -113,871 | -165,456 | -158,090 |
Net Change In Cash | 178,032 | 60,281 | 27,148 | 6,149 |
Cost of Revenue | 89,817 | |||
Free Cash Flow | -73,206 | -145,760 | -171,509 | 1,948 |
Cash | 91,139 | 143,991 | 108,033 | 149,948 |
Basic Shares | 1,513,810 | 1,206,440 | 967,242 | 934,833 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.23 |
2024-09-30 | -$0.01 |
2024-06-30 | $0.24 |
2024-03-31 | -$0.18 |
